Larimar Therapeutics, Inc.

NASDAQ:LRMR

Biotechnology

Healthcare
$3.23 +0.99%

+$0.04 today

Market cap
$337.45M
Beta
0.82
P/E (TTM)
-1.8
EPS (TTM)
-$1.95
52W Low $2.22High $6.42

Volume 1.41M

Average 1.73M

LRMR Total Equity

Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.

Larimar Therapeutics, Inc.NASDAQ: LRMR

Total Equity · Q1 FY2026 · quarter ended Mar 2026

Total equity rises 9.5% from a year ago

Total equity stood at $158.03M at the end of Q1 FY2026, up 9.5% from a year earlier and up 102.4% from the prior quarter. Over 3 fiscal years it compounded at -11.0% a year.

Context

  • Total equity amounted to 75.8% of total assets at the end of Q1 FY2026, down 9.0 pp from a year earlier.
  • Total equity increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether total equity keeps rising in the next quarterly balance sheet after a +9.5% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$158.03M+102.4% QoQ
Last fiscal yearDec 2025
$78.09M-54.6% YoY
Year agoMar 2025
$144.27M+9.5% since
Total Equity past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+9.5%——
1 year-54.6%——
3-year CAGR-11.0%——
5-year CAGR——
10-year CAGR——

Total Equity history

USD · from the balance sheet

Latest · FY2025
78.09M USD
Year-over-year change
-54.6%
4-year CAGR
+4.9%

Total Equity vs competitors

How LRMR compares with its peers on the latest reported figures

  • Peers report in different currencies, so total equity is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +9.5% is the 6th highest of 11, against a peer median of +3.6%.
  • Total equity amounts to 75.8% of total assets for LRMR, versus a peer median of 77.9%.
LRMR Competitors
Total Equity for LRMR and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
AMRNAmarin Corporation plcMar 2026$449.41M USD-5.1%-8.3%69.6%
ALTAltimmune, Inc.Mar 2026$283.99M USD+99.8%+6.7%84.6%
ENGNenGene Holdings Inc.Apr 2026$255.17M USD+12.3%+9.6%83.0%
ANROAlto Neuroscience, Inc.Mar 2026$243.37M USD+75.0%—88.1%
LXEOLexeo Therapeutics, Inc. Common StockMar 2026$231.5M USD+162.7%—92.5%
DBVTDBV Technologies S.A.Mar 2026$207.9M USD+7136.3%-4.6%78.0%
ANNXAnnexon, Inc.Mar 2026$204.53M USD-16.1%-2.9%77.8%
KYTXKyverna Therapeutics, Inc.Mar 2026$195.58M USD-12.7%+70.7%76.1%
LRMRLarimar Therapeutics, Inc.Mar 2026$158.03M USD+9.5%-11.0%75.8%
KRROKorro Bio, Inc.Mar 2026$119.63M USD-13.9%—65.2%
ACIUAC Immune S.A.Mar 2026CHF 31.53M CHF-66.7%-35.7%22.9%
Peer median (excluding LRMR) —+3.6%-2.9%77.9%

Competitors are the stored peer set for LRMR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents70.1M26.83M26.75M33.22M85.41M
Short-term Investments091.6M60.04M150.24M51.44M
Net Receivables208K001.05M747K
Inventory00000
Other Current Assets279K238K709K517K253K
Total Current Assets72.2M120.74M90.18M195.3M142.02M
Property, Plant & Equipment (Net)4.46M3.69M3.76M3.72M2.69M
Goodwill00000
Intangible Assets00000
Long-term Investments1.34M01.34M00
Tax Assets00000
Other Non-current Assets669K1.98M659K1.2M1.13M
Total Non-current Assets6.46M5.67M5.76M4.92M3.82M
Total Assets78.67M126.41M95.94M200.23M145.84M
Account Payables1.66M1.69M1.28M2.42M5.22M
Short-term Debt00001.11M
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities000054.69M
Total Current Liabilities8.85M10.71M9.51M24.36M64.8M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities00000
Total Non-current Liabilities5.41M4.8M4.71M4.06M2.96M
Total Liabilities14.25M15.5M14.22M28.41M67.76M
Common Stock18K43K43K64K83K
Retained Earnings(116.25M)(151.61M)(188.55M)(269.16M)(434.83M)
Accumulated OCI(0)(31K)81K148K54K
Other Stockholders Equity00000
Minority Interest00000
Total Equity64.41M110.9M81.72M171.81M78.09M
Total Debt6M5.41M5.55M5.12M4.07M
Net Debt(64.1M)(21.42M)(21.2M)(28.1M)(81.35M)

Larimar Therapeutics, Inc.

NASDAQ:LRMR

Intrinsic Alpha fair value

Locked

Current Price

$3.23

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.